Categories: NewsPharmaceutical

BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Oili Halonen

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 8 December 2023 at 3.30 p.m. (EET)

BBS-Bioactive Bone Substitutes Oyj – Managers’ Transactions – Oili Halonen

____________________________________________

Person subject to the notification requirement
Name: Halonen Oili
Position: Closely associated person
(1):Person Discharging Managerial Responsibilities In Issuer
Name: Halonen Jarmo
Position: Member of the Board
Issuer: BBS Bioactive Bone Substitutes Oyj
LEI: 743700BYSBP0PCR6N767
Notification type: INITIAL NOTIFICATION
Reference number: 743700BYSBP0PCR6N767_20231208124156_4

____________________________________________

Transaction date: 2023-12-07
Venue not applicable
Instrument type: SHARE
ISIN: FI4000260583
Nature of the transaction: SUBSCRIPTION

Transaction details
(1): Volume: 2,475 Unit price: 0.4 EUR

Aggregated transactions
(1): Volume: 2,475 Volume weighted average price: 0.4 EUR

For more information, please contact:

Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

BBS in brief

BBS -Bioactive Bone Substitutes Plc is a orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company’s headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Staff

Recent Posts

New APOE4 App Uses AI Digital Twins to Help 25% of Population at High Alzheimer’s Risk

Phoenix platform matches users with genetically similar people to predict which interventions actually work. SINGAPORE,…

1 day ago

Premier Health Partners – Notice of Data Event

DAYTON, Ohio, July 18, 2025 /PRNewswire/ -- Premier Health Partners ("Premier Health") is providing notice…

2 days ago

The American College of Surgeons Advances New Clinical Data Strategy to Improve Surgical Care for Patients

Collaboration with Epic is first phase of a multiyear project that will include multiple technology…

2 days ago

PEN America Acquires OnlineSOS, Expanding Commitment to Digital Safety and Free Expression

NEW YORK, July 18, 2025 /PRNewswire/ -- In a strategic move underscoring their shared commitment…

2 days ago

Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management

BEIJING, July 18, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader…

2 days ago